ArticleJournal of translational autoimmunity2021
Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome.
Article in Journal of translational autoimmunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 43 citations in OpenAlex.
- Design and Implementation of an Automated Interpretation Algorithm for Lupus Anticoagulant Functional Testing.International journal of laboratory hematology · 2026Article
- Detection of Diagnostic Antibodies in Immune-Mediated Diseases: A Focus on Antigens and Technologies.Chembiochem : a European journal of chemical biology · 2026Review
- Reclassification of obstetric antiphospholipid syndrome under the 2023 ACR/EULAR criteria: risk of under-recognition in patients with non-criteria antibodies and clinical implications.Frontiers in medicine · 2026Article
- Heterogeneity of antiphospholipid antibody profiles in a clinical cohort and association with distinct clinical features.RMD open · 2025Article
- Role of antiphospholipid antibodies in kidney disease: Risk factors, immunopathogenesis, and diagnosis.World journal of nephrology · 2025Review
- Activated Complement System's Impact in Antiphospholipid Syndrome Thrombosis: From Pathophysiology to Treatment.Journal of clinical medicine · 2025Review
- The absence of standardization in antiphospholipid antibody testing may favor the use of 99th percentile cutoffs in antiphospholipid syndrome classification.Research and practice in thrombosis and haemostasis · 2025Article
- The New Occurrence of Antiphospholipid Syndrome in Severe COVID-19 Cases with Pneumonia and Vascular Thrombosis Could Explain the Post-COVID Syndrome.Biomedicines · 2025Article
- Impact of the 2023 ACR/EULAR Classification Criteria in Women with Primary Antiphospholipid Syndrome during Pregnancy.Diagnostics (Basel, Switzerland) · 2024Article
- Antiphospholipid antibodies in patients with antiphospholipid syndrome.Biochemia medica · 2024Review
- Non-criteria autoantibodies in antiphospholipid syndrome may be associated with underlying disease activity.Irish journal of medical science · 2024Article
- Insight into antiphospholipid syndrome: the role and clinical utility of neutrophils extracellular traps formation.Thrombosis journal · 2024Article
- Determining Thrombogenicity: Using a Modified Thrombin Generation Assay to Detect the Level of Thrombotic Event Risk in Lupus Anticoagulant-Positive Patients.Biomedicines · 2023Article
- Antiphospholipid Antibodies and Vascular Thrombosis in Patients with Severe Forms of COVID-19.Biomedicines · 2023Article
- Antibodies to Domain I βDoklady. Biochemistry and biophysics · 2023Article
- Antiphospholipid Antibody Testing for Anti-cardiolipin and Anti-β2 Glycoprotein I Antibodies Using Chemiluminescence-Based Panels.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Laboratory Testing for Non-criteria Antiphospholipid Antibodies: Antibodies Toward the Domain I of Beta2-Glycoprotein I (aDI).Methods in molecular biology (Clifton, N.J.) · 2023Article
- Laboratory Testing for Non-criteria Antiphospholipid Antibodies: Anti-phosphatidylserine/Prothrombin Antibodies (aPS/PT).Methods in molecular biology (Clifton, N.J.) · 2023Article
- Differences in Antiphospholipid Antibody Profile between Patients with Obstetric and Thrombotic Antiphospholipid Syndrome.International journal of molecular sciences · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis of antiphospholipid syndrome (APS) relies on the detection of antiphospholipid antibodies (aPL). Currently, lupus anticoagulant (LA), anticardiolipin (aCL), and antibeta2-glycoprotein I antibodies (aβ2GPI) IgG or IgM are included as laboratory criteria, if persistently present. LAC measurement remains a complicated procedure with many pitfalls and interfered by anticoagulant therapy. Solid-phase assays for aCL and aβ2GPI show interassay differences. These methodological issues make the laboratory diagnosis of APS challenging. In the interpretation of aPL results, antibody profiles help in identifying patients at risk. Other aPL, such as antibodies against the domain I of beta2-glycoprotein (aDI) and antiphosphatidylserine-prothrombin (aPS/PT) antibodies have been studied in the last years and may be useful in risk stratification of APS patients. Because of the methodological shortcomings of immunological and clotting assays, these non-criteria aPL may be useful in patients with incomplete antibody profiles to confirm or exclude the increased risk profile. This manuscript will focus on the laboratory aspects, the clinical relevance of assays and interpretation of aPL results in the diagnosis of APS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.